Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
Table 1
Baseline characteristics.
ITT population ()
Baseline characteristics
Age (years), mean (SD)
62.8 (15.0)
Male, (%)
13 (54.2)
Caucasian ethnicity, (%)
24 (100.0)
Time from MO secondary to CRVO diagnosis (days), median (IQR)
7.6 (3.0, 15.2)
IOP in study eye (mmHg), mean (SD)
15.7 (3.0)
Baseline BCVA score (ETDRS) in contralateral eye, letters, mean (SD)
81.0 (9.3)
Patients with any relevant medical history/concomitant pathology
23 (95.8)
Arterial hypertension
17 (70.8)
Dyslipidaemia
8 (33.3)
Cataracts
5 (20.8)
Anxiety
3 (12.5)
Diabetes mellitus
3 (12.5)
Obesity
3 (12.5)
Others
17 (70.8)
BCVA: best-corrected visual acuity; CRVO: central retinal vein occlusion; ETDRS: early treatment diabetic retinopathy study; IOP: intraocular pressure; IQR: interquartile range; ITT: intention-to-treat; MO: macular oedema; SD: standard deviation. Conditions experienced by <10% of the patient population.
